EUVIMEDEUVIMED entdecken
Crossref

Clinical Impact of Androgen Receptor–Suppressing miR-146b Expression in Papillary Thyroid Cancer Aggressiveness

Chen-Kai Chou, Shun-Yu Chi, Yi-Yung Hung, Yi-Chien Yang, Hung-Chun Fu, Jia-He Wang, Chueh-Chen Chen, Hong-Yo Kang iD

The Journal of Clinical Endocrinology & Metabolism · 18.10.2023 · 108 (11) · 2852-2861

DOI: 10.1210/clinem/dgad279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 23.05.2023. Verfasst von Chen-Kai Chou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of M…. Hauptthemen laut MEDLINE: Carcinoma, Papillary, MicroRNAs, Receptors, Androgen, Thyroid Cancer, Papillary. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital-Kaohsiung Medical Center, Ministry of Science and Technology of the Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. Dysregulated expression of miR-146b and androgen receptor (AR) has been shown to play critical roles in tumorigenesis in PTC. However, the mechanistic and clinical association between AR and miR-146b is not fully understood.

Objective

The purpose was to investigate miR-146b as the potential AR target miRNA and its involvement in advanced tumor characteristics of PTC.

Methods

Expression of AR and miR-146b were assessed in frozen and formalin-fixed paraffin-embedded tissue samples from PTC and adjacent normal thyroid specimens by quantitative real-time polymerase chain reaction, and their correlation was examined. Human thyroid cancer cell lines BCPAP and TPC-1 were used to evaluate the effect of AR on miR-146b signaling. Chromatin immunoprecipitation (ChIP) assays were performed to determine whether AR binds to the miR-146b promoter region.

Results

Pearson correlation analysis confirmed significant inverse correlation between miR-146b and AR expression. Overexpressing AR BCPAP and TPC-1 cells showed relatively lower miR-146b expression. ChIP assay revealed that AR might bind to the androgen receptor element located on the promoter region of miRNA-146b gene, and overexpression of AR suppresses miR-146b-mediated tumor aggressiveness. The low AR/high miR-146b PTC patient group was associated with advanced tumor characteristics, including higher tumor stage, lymph node metastasis, and worse treatment response.

Conclusion

To sum up, miR-146b is a molecular target of AR transcriptional repression; therefore, AR suppresses miR-146b expression to reduce PTC tumor aggressiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, PapillaryMicroRNAsReceptors, AndrogenThyroid Cancer, PapillaryThyroid NeoplasmsHumansAndrogensCell Line, TumorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

microRNAneoplasmsteroid hormone receptortumor prognosis

Substanzen

AndrogensMicroRNAsReceptors, AndrogenMIRN146 microRNA, human

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
  • Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
  • Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
  • Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
  • Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
  • Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Taoyuan City 83301, Taiwan.

ORCID-Profile: Hong-Yo Kang

Förderung

  • Chang Gung Memorial Hospital-Kaohsiung Medical Center
  • Ministry of Science and Technology of the Republic of China

Zitieren

APA

Chou, C. K., Chi, S. Y., Hung, Y. Y., Yang, Y. C., Fu, H. C., Wang, J. H., Chen, C. C., & Kang, H. Y. (2023). Clinical Impact of Androgen Receptor–Suppressing miR-146b Expression in Papillary Thyroid Cancer Aggressiveness. The Journal of Clinical Endocrinology & Metabolism, 108(11), 2852-2861. https://doi.org/10.1210/clinem/dgad279

Vancouver

Chou CK, Chi SY, Hung YY, Yang YC, Fu HC, Wang JH, et al. Clinical Impact of Androgen Receptor–Suppressing miR-146b Expression in Papillary Thyroid Cancer Aggressiveness. The Journal of Clinical Endocrinology & Metabolism. 2023;108(11):2852-2861. doi:10.1210/clinem/dgad279

BibTeX
@article{Chou2023,
  author = {Chou, Chen-Kai and Chi, Shun-Yu and Hung, Yi-Yung and Yang, Yi-Chien and Fu, Hung-Chun and Wang, Jia-He and Chen, Chueh-Chen and Kang, Hong-Yo},
  title = {Clinical Impact of Androgen Receptor–Suppressing miR-146b Expression in Papillary Thyroid Cancer Aggressiveness},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {11},
  pages = {2852--2861},
  doi = {10.1210/clinem/dgad279}
}
Kostenlos starten →